Evidence map›Paper›PMID 41792203›Full record

ArticleScientific reports2026

Cannabidiolic acid as a modulator of lipid metabolism in the liver of rats with metabolic-associated steatotic liver disease.

Piotr Franciszek Kurzyna, Patryk Chabowski, Mateusz Zwierz, Ewa Harasim-Symbor, Janusz Dzięcioł, Justyna Klimek, Piotr Ryszkiewicz, Adrian Chabowski, Karolina Konstantynowicz-Nowicka

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Piotr Franciszek KurzynaDepartment of Physiology, Medical University of Bialystok, 15-222, Bialystok, Poland. piotr.kurzyna@umb.edu.pl.
Patryk ChabowskiDepartment of Physiology, Medical University of Bialystok, 15-222, Bialystok, Poland.
Mateusz ZwierzDepartment of Physiology, Medical University of Bialystok, 15-222, Bialystok, Poland.
Ewa Harasim-SymborDepartment of Physiology, Medical University of Bialystok, 15-222, Bialystok, Poland.
Janusz DzięciołDepartment of Human Anatomy, Medical University of Bialystok, 15-222, Bialystok, Poland.
Justyna KlimekDepartment of Human Anatomy, Medical University of Bialystok, 15-222, Bialystok, Poland.
Piotr RyszkiewiczDepartment of Experimental Physiology and Pathophysiology, Medical University of Bialystok, 15-222, Bialystok, Poland.
Adrian ChabowskiDepartment of Physiology, Medical University of Bialystok, 15-222, Bialystok, Poland.
Karolina Konstantynowicz-NowickaDepartment of Physiology, Medical University of Bialystok, 15-222, Bialystok, Poland.

Funding

Ministerstwo Edukacji i Nauki PN/01/0003/2022
6 · The paper itself

Abstract

This study investigated the effects of cannabidiolic acid (CBDA) on hepatic lipid metabolism in a rat model of metabolic dysfunction-associated steatotic liver disease (MASLD), addressing the need for natural therapeutic compounds targeting lipid metabolism disorders. Male Wistar rats were fed a standard diet or a high-fat diet (HFD) for 8 weeks. During the last 14 days, half of the rats received CBDA intragastrically (0.1 mg/kg BW). The hepatic lipid fractions were analyzed via gas-liquid chromatography, and protein expression was assessed via Western blotting and immunohistochemistry. Compared with the control diet, the HFD significantly increased the expression of fatty acid transporters CD36, FATP5, and FABPpm and elevated the levels of free fatty acids (FFAs), triacylglycerols, diacylglycerols, and phospholipids compared with controls. CBDA treatment in HFD-fed rats significantly decreased CD36, FABPpm, and FATP5 expression as well as total diacylglycerol and phospholipid concentrations. CBDA also decreased the saturated fatty acid content in the FFA and phospholipid fractions while increasing omega-3 polyunsaturated fatty acids in the diacylglycerol and triacylglycerol fractions. CBDA ameliorated HFD-induced hepatic steatosis by modulating fatty acid transporter expression, reducing harmful lipid accumulation and improving fatty acid composition. These findings suggest the potential of CBDA as a therapeutic agent for MASLD through the targeting of multiple dysregulated pathways in hepatic lipid metabolism, potentially limiting disease progression.

Indexed as

CannabinoidsLipid MetabolismLiverNon-alcoholic Fatty Liver DiseaseAnimalsFatty Acids, UnsaturatedMaleRatsRats, Wistarcannabidiolic acidCannabinoidsFatty Acids, UnsaturatedCannabidiolic acid (CBDA)Fatty acid transportersHepatic lipid metabolismMetabolic-associated steatotic liver disease (MASLD)Phytocannabinoids

Identifiers

PMID41792203
PMCPMC12979676

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.